YAFO Capital represents multiple potential domestic and overseas buyers seeking the following assets

Collaboration Regions: China or global rights (Licensing, Co-development, M&A)

Asset Requirements

Therapeutic Area and Indications:
Central Nervous System (CNS): Treatment for depression, schizophrenia, insomnia, anxiety, Parkinson’s disease (PD), social anxiety disorder, PTSD.
Anesthesia and Pain Management: Acute pain, inflammatory pain, chronic pain, anesthesia, sedation, muscle relaxants, and muscle relaxant antagonists.
Gastroenterology: Inflammatory bowel disease (IBD).
Respiratory: Asthma and chronic obstructive pulmonary disease (COPD).
Reproductive Health: Andrology and gynecology health.

For the above indications, small molecules are preferred from pre-clinical to Phase II stages.
Chronic Diseases: Diabetes, hypertension, hyperlipidemia, hyperuricemia, OA, UC/IBD.
Gastrointestinal: New drugs for endoscopic anesthesia.
Anti-Infection: Novel antibiotics.
Oncology: NSCLC resistant to third-generation EGFR-TKIs.

For the above indications, assets in Phase II-III stages are preferred.
Cardiovascular, Nephrology, and Autoimmune Diseases: siRNA/ASO first-in-class (FIC) drugs.
Protein Replacement Therapy: mRNA-based treatments.
Cancer and Epigenetics.
Rare Diseases and RNA Writing Technology.

For the above indications, assets in the pre-clinical stage are preferred.
Autoimmune Diseases: Durable monoclonal antibody (mAb) and bispecific antibody (bsAb) projects, globally competitive and in the top three, with best-in-class potential and differentiated features.
Dermatology: Mid-to-late-stage assets, including but not limited to acne, atopic dermatitis, psoriasis, and actinic keratosis.


Should you need further information or have any questions, please feel free to contact us at [Ms. Wendi Xiang, wxiang@yafocapital.com]